posit quarter come gilead
gilead report revenu rel in-line consensu
y/i though note sequenti declin due
season non-gaap net incom grew y/i non-gaap ep
beat consensu gilead end quarter cash
note first earn call daniel day leadership
gilead look next chapter
commerci updat hiv revenu continu grow y/i basi
although compani lost ground europ
truvada gener competitor gilead longer regimen among
naiv patient us hiv growth larg driven uptak biktarvi
could also help europ importantli hcv seem stabil new
patient start last quarter sequenti increas
though partial due stock author
gener depart correct order
yescarta continu steadi growth yescarta revenu came
sequenti growth patient treat date us
center author eu reimburs remain goal
talk on-going propos current open comment june
could increas fund new technolog
come ahead gilead could ceo daniel day highlight
new program cell therapi inflamm nash futur direct
drive growth filgotinib nearest submiss expect
rheumatoid arthriti ra fda meet could
determin timelin us whether manta studi requir
approv also highlight import bolster late
stage pipelin cash manag view top
what next gilead clariti expect later year day
plan give updat goal compani later key point
highlight call first kite becom separ busi unit
fulli focus cell therapi help gilead solidifi leadership posit
car-t registr studi nhl due readout
studi mcl read inflammatori also
prioriti sg spend plan selonsertib launch redirect
toward prep filgotinib also identifi top prioriti spend
capit specif bolster compani late stage pipelin
gilead nash failur gilead longer
pivot nash least compani still atla combin
trial test doublet selonsertib firsocostat cilofexor read later
well new collabor studi novo nordisk nvo nr
combin cilofexor fxr agonist firsocostat inhibitor novo
analogu semaglutid gilead also earlier-stag collabor scholar
 nr yuhan ks nr recent collabor
insitro privat discov new nash target therapeut use machin
learn platform three remain nash genfit gnftf
nr elafibranor intermedi data allergan nr cenicriviroc
intermedi data madrig nr initi
recent intercept nr data impress februari though
compani may still potenti file nda oca nash fibrosi vike
 buy go galm glmd buy
go aramchol well note howev
cash gilead could bolster nash pipelin acquir late stage asset
leapfrog back lead
inflammatori diseas filgo beat nr finch trial
report posit data filgotinib ra see note link
data come later year though manta still limit factor
determin safeti relat testicular toxic talk fda
could result earlier file plan filgotinib also
move forward crohn ulcer coliti uc well multipl
indic inflammatori market huge humira gener
definit harvoni-s market problem
alreadi multipl player includ upadacitinib
nda review ra approv olumi xeljanz factor
could drive adopt filgo best-in-class safeti profil approv
drug black box warn howev filgotinib achiev statist
signific improv vs humira though numer improv
upadacitinib
model chang revenu estim reduc slightli
though improv non-gaap margin drive increas non-gaap
ep estim estim revenu lower
result lower non-gaap ep
exhibit guidanc issu
exhibit gilead remain top us face increas competit eu
exhibit us market dynam hiv
exhibit gilead us share treatment nave hiv patient
exhibit truvada prep continu grow us
exhibit descovi prep trial demonstr superior safeti truvada
exhibit hcv show sign stabil
exhibit hcv patient initi sovaldi-bas regimen stabl three quarter
pipelin asset focu
exhibit finch data demonstr posit efficaci filgotinib
thousand except per share data
contract revenu
cog associ car-t
royalti merck us sale harvoni sovaldi
interest incom net
net loss attribut non control interest
net incom attribut gilead
basic ep attribut gilead sharehold
gaap dilut ep attribut gilead sharehold
compani report maxim group estim
